Description: Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Home Page: www.cadrenal.com
822 A1A North
Ponte Vedra,
FL
32082
United States
Phone:
904 300 0701
Officers
| Name | Title |
|---|---|
| Mr. Quang X. Pham | Chairman & CEO |
| Mr. Matthew K. Szot CPA, CPA | Co-Founder & CFO |
| Dr. Douglas W. Losordo FACC, FAHA, M.D. | Chief Medical Officer |
| Mr. Jeffrey Cole | Chief Operating Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.6389 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-01-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |